NBIO - Nascent Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1250
+0.0050 (+4.17%)
At close: 11:26AM EST
Stock chart is not supported by your current browser
Previous Close0.1200
Open0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1150 - 0.1375
52 Week Range0.0520 - 0.2100
Volume47,678
Avg. Volume7,588
Market Cap4.52M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Nascent Biotech, Inc. CEO Interviewed by The Wall Street Analyzer

    San Diego, CA, Feb. 05, 2020 -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) is pleased to release a recent interview with company President | CEO Sean Carrick, on.

  • GlobeNewswire

    Nascent Biotech Founder, Dr. Mark Glassy, Will Present at the Clinical Operation in Oncology Trials Meeting, in San Diego in February

    SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (NBIO) founder Dr. Mark C. Glassy will be presenting on “Navigating the Unique Challenges Presented in Immune Oncology trials” in San Diego on February 12th. The meeting will be attended by influential leaders in the Pharmaceutical and Investment community.

  • GlobeNewswire

    Nascent Biotech, Inc. Featured in New Research Update

    San Diego, CA, Jan. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO), an emerging biotech company, with IND Clearance and IRB approval to begin Clinical trials for Brain Cancer, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company. The updated report provides an overview of recent events, new initiatives, and the Company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed and requested by email at mp@marblearchusa.com.

  • GlobeNewswire

    Nascent Biotech Receives One Million Dollar Commitment From TRITON FUNDS LP

    SAN DIEGO, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO), a biopharmaceutical company focusing on the development of monoclonal antibodies for the treatment of various types of cancers, announces an agreement with TRITON FUNDS LP. “Brain cancer is a severely underserved market affecting up to 25,000 new patients annually in the US alone.  The metastatic patient population adds an additional 175,000 patients.  We are excited to finally begin treating patients,” added Mr. Carrick.

  • GlobeNewswire

    Nascent Biotech Has Entered into an Agreement to Perform Phase I Clinical Study for Brain Cancer

    San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO), today announced they have entered into a contractual agreement in Orange County, CA to conduct Phase I human clinical trials on Nascent antibody, Pritumumab, for the treatment of brain cancer.  Pritumumab, a unique monoclonal antibody that appears to bind selectively to a number of epithelial cancers, had been previously studied in Japan with very promising results in the treatment of brain cancer.

  • GlobeNewswire

    Nascent Biotech Officers Convert Liability to Stock in the Company

    San Diego, CA, June 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) announced today that two of its Senior Officers have converted the Company’s liability to them to common stock. Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value.  The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth. Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an IND application before the FDA required for Clinical trials.  Its products are not commercially available.

  • ACCESSWIRE

    Emerging Markets Report: On a Human Level

    Today's featured company Nascent Biotech, Inc. (NBIO) is unique among all our previous offerings. Today's offering is complicated, at least by small cap standards and, well, perhaps typical of a company whose cancer technology has been created and developed since 1982, and which has now just received an incredibly critical permission to enter human trials for brain cancer. In 1982, Japan-based Hideaki Hagiwara, Ph. D was seeking a way to help treat his mother's cervical cancer and approached U.S.-based Dr. Mark Glassy, a professor at UCSD.

  • GlobeNewswire

    Nascent Biotech Moves Corporate Offices to San Diego

    San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) has moved their corporate offices to San Diego, CA. Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials in brain cancer.  Its products are not commercially available.